Targeting activated integrin αvβ3 with patient-derived antibodies impacts late-stage multiorgan metastasis

Clinical and Experimental Metastasis

Volumn 27, Issue 4, 2010, Pages 217-231

  Staflin, Karin ^a   Krueger, Joseph S ^a   Hachmann, Janna ^a   Forsyth, Jane S ^a   Lorger, Mihaela ^a   Steiniger, Sebastian C J ^a   Mee, Jenny ^a   Pop, Cristina ^b   Salvesen, Guy S ^b   Janda, Kim D ^a   Felding Habermann, Brunhilde ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Activated integrin; Advanced metastasis; Patient antibodies; Treatment

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CASPASE 3; RECOMBINANT ANTIBODY; SCFV ANTIBODY; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIGAND BINDING; METASTASIS; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; TREATMENT RESPONSE; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ANIMALS; CASPASE 3; DISEASE MODELS, ANIMAL; HUMANS; INTEGRIN ALPHAVBETA3; MICE; MICE, SCID; NEOPLASM METASTASIS; SINGLE-CHAIN ANTIBODIES;

EID: 77953242479     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-010-9320-5     Document Type: Article

References (47)

1. PS Steeg 2008 Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program Clin Cancer Res 14 12 3643 3645 10.1158/1078-0432.CCR-08-1135 18559575
2. CR Cooper CH Chay KJ Pienta 2002 The role of αvβ3 in prostate cancer progression Neoplasia 4 3 191 194 10.1038/sj.neo.7900224 1:CAS:528:DC%2BD38XksFGnu74%3D 11988838
3. PC Brooks AM Montgomery M Rosenfeld, et al.. 1994 Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 79 7 1157 1164 10.1016/0092-8674(94)90007-8 1:CAS:528: DyaK2MXivVWqu7o%3D 7528107
4. M Lim S Guccione T Haddix, et al.. 2005 Αvβ3 integrin in central nervous system tumors Hum Pathol 36 6 665 669 10.1016/j.humpath.2005.03. 014 1:CAS:528:DC%2BD2MXlvVWnu78%3D 16021573 (Pubitemid 40922573)
5. B Felding-Habermann TE O'Toole JW Smith, et al.. 2001 Integrin activation controls metastasis in human breast cancer Proc Natl Acad Sci USA 98 4 1853 1858 10.1073/pnas.98.4.1853 1:CAS:528:DC%2BD3MXhsVWisLs%3D 11172040 (Pubitemid 32165587)
6. JS Desgrosellier LA Barnes DJ Shields, et al.. 2009 An integrin αvβ3-c-Src oncogenic unit promotes anchorage-independence and tumor progression Nat Med 15 10 1163 1169 10.1038/nm.2009 1:CAS:528:DC%2BD1MXhtV2gsbvF 19734908
7. SM Albelda SA Mette DE Elder, et al.. 1990 Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression Cancer Res 50 20 6757 6764 1:CAS:528:DyaK3cXmt1ylurs%3D 2208139
8. MC Gingras E Roussel JM Bruner CD Branch RP Moser 1995 Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue J Neuroimmunol 57 1-2 143 153 10.1016/0165-5728(94)00178-Q 1:CAS:528:DyaK2MXksV2jtb8%3D 7535788
9. CL Gladson S Hancock MM Arnold OM Faye-Petersen RP Castleberry DR Kelly 1996 Stage-specific expression of integrin αvβ3 in neuroblastic tumors Am J Pathol 148 5 1423 1434 1:STN:280:DyaK283gvVWhsw%3D%3D 8623914 (Pubitemid 26135886)
10. Q Ding J Stewart Jr MA Olman MR Klobe CL Gladson 2003 The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged J Biol Chem 278 41 39882 39891 10.1074/jbc.M304685200 1:CAS:528:DC%2BD3sXnvFamsro%3D 12881526 (Pubitemid 37248551)
11. PC Brooks RA Clark DA Cheresh 1994 Requirement of vascular integrin alpha v beta 3 for angiogenesis Science 264 5158 569 571 10.1126/science.7512751 1:CAS:528:DyaK2cXjt1Sis7w%3D 7512751
12. Y Fujita R Abe H Shimizu 2008 Clinical approaches toward tumor angiogenesis: past, present and future Curr Pharm Des 14 36 3820 3834 10.2174/138161208786898680 1:CAS:528:DC%2BD1MXhsVCitbg%3D 19128235
13. W Cai X Chen 2006 Anti-angiogenic cancer therapy based on integrin αvβ3 antagonism Anticancer Agents Med Chem 6 5 407 428 10.2174/187152006778226530 1:CAS:528:DC%2BD28Xos1Gqt7w%3D 17017851 (Pubitemid 44708870)
14. JS Desgrosellier DA Cheresh 2010 Integrins in cancer: biological implications and therapeutic opportunities Nat Rev Cancer 10 1 9 22 10.1038/nrc2748 1:CAS:528:DC%2BD1MXhsF2hsLzI 20029421
15. M Paolillo MA Russo M Serra L Colombo S Schinelli 2009 Small molecule integrin antagonists in cancer therapy Mini Rev Med Chem 9 12 1439 1446 10.2174/138955709789957404 1:CAS:528:DC%2BC3cXit1Ci 19929817
16. M Schottelius B Laufer H Kessler HJ Wester 2009 Ligands for mapping αvβ3-integrin expression in vivo Acc Chem Res 42 7 969 980 10.1021/ar800243b 1:CAS:528:DC%2BD1MXms1Knt78%3D 19489579
17. B Felding-Habermann RA Lerner A Lillo, et al.. 2004 Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis Proc Natl Acad Sci USA 101 49 17210 17215 10.1073/pnas.0407869101 1:CAS:528:DC%2BD2cXhtFagu7fK 15563590 (Pubitemid 39627799)
18. PJ Carter 2006 Potent antibody therapeutics by design Nat Rev Immunol 6 5 343 357 10.1038/nri1837 1:CAS:528:DC%2BD28XjslOhu7o%3D 16622479
19. AF Chambers 2009 MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma? Cancer Res 96 13 5292 5293 10.1158/0008-5472.CAN-09-1528
20. A Hollestelle M Schutte 2009 Comment Re: MDA-MB-435 and M14 cell lines: identical but not M14 Melanoma? Cancer Res 69 19 7893 10.1158/0008-5472.CAN-09- 2396 1:CAS:528:DC%2BD1MXht1Skt7bL 19723654
21. EI Deryugina JP Quigley 2008 Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis Histochem Cell Biol 130 6 1119 1130 10.1007/s00418-008-0536-2 1:CAS:528:DC%2BD1cXhsVSjsrzO 19005674
22. TV Byzova W Kim RJ Midura EF Plow 2000 Activation of integrin αvβ3 regulates cell adhesion and migration to bone sialoprotein Exp Cell Res 254 2 299 308 10.1006/excr.1999.4765 1:CAS:528:DC%2BD3cXksl2qsw%3D%3D 10640428 (Pubitemid 30080586)
23. BH Luo CV Carman TA Springer 2007 Structural basis of integrin regulation and signaling Annu Rev Immunol 25 619 647 10.1146/annurev.immunol.25.022106. 141618 1:CAS:528:DC%2BD2sXltlansrc%3D 17201681 (Pubitemid 46697919)
24. K Ajroud T Sugimori WH Goldmann DM Fathallah JP Xiong MA Arnaout 2004 Binding affinity of metal ions to the CD11b a-domain is regulated by integrin activation and ligands J Biol Chem 279 24 25483 25488 10.1074/jbc.M402901200 1:CAS:528:DC%2BD2cXksFygsbw%3D 15070893 (Pubitemid 38756806)
25. JP Xiong T Stehle SL Goodman MA Arnaout 2003 Integrins, cations and ligands: making the connection J Thromb Haemost 1 7 1642 1654 10.1046/j.1538-7836.2003.00277.x 1:CAS:528:DC%2BD2cXktFOjtLs%3D 12871301
26. JP Xiong T Stehle SL Goodman MA Arnaout 2003 New insights into the structural basis of integrin activation Blood 102 4 1155 1159 10.1182/blood-2003-01-0334 1:CAS:528:DC%2BD3sXmsFWksL8%3D 12714499 (Pubitemid 36988017)
27. CD Buckley D Pilling NV Henriquez, et al.. 1999 RGD peptides induce apoptosis by direct caspase-3 activation [see comments] Nature 397 6719 534 539 10.1038/17409 1:CAS:528:DyaK1MXhtlCkurs%3D 10028971 (Pubitemid 29093253)
28. S Roy CI Bayly Y Gareau, et al.. 2001 Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide Proc Natl Acad Sci USA 98 11 6132 6137 10.1073/pnas.111085198 1:STN:280: DC%2BD3M3pt1Wlsw%3D%3D 11353841 (Pubitemid 32488205)
29. CD Anuradha S Kanno S Hirano 2000 RGD peptide-induced apoptosis in human leukemia HL-60 cells requires caspase-3 activation Cell Biol Toxicol 16 5 275 283 10.1023/A:1026758429238 1:CAS:528:DC%2BD3MXhtVeiurc%3D 11201051 (Pubitemid 32059898)
30. MS Aguzzi C Giampietri F De Marchis, et al.. 2004 RGDS peptide induces caspase 8 and caspase 9 activation in human endothelial cells Blood 103 11 4180 4187 10.1182/blood-2003-06-2144 1:CAS:528:DC%2BD2cXkvVyit70%3D 14982875 (Pubitemid 38685360)
31. RU Janicke P Ng ML Sprengart AG Porter 1998 Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis J Biol Chem 273 25 15540 15545 10.1074/jbc.273.25.15540 1:CAS:528:DyaK1cXktVSmtbo%3D 9624143 (Pubitemid 28298165)
32. E Devarajan AA Sahin JS Chen, et al.. 2002 Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance Oncogene 21 57 8843 8851 10.1038/sj.onc.1206044 1:CAS:528:DC%2BD38XpsFShu78%3D 12483536 (Pubitemid 36132404)
33. TV Byzova R Rabbani SE D'Souza EF Plow 1998 Role of integrin αvβ3 in vascular biology Thromb Haemost 80 5 726 734 1:CAS:528:DyaK1cXnsF2jtbg%3D 9843163
34. DG Stupack DA Cheresh 2004 Integrins and angiogenesis Curr Top Dev Biol 64 207 238 10.1016/S0070-2153(04)64009-9 1:CAS:528:DC%2BD2MXksFyntL8%3D 15563949 (Pubitemid 39752398)
35. DG McNeel J Eickhoff FT Lee, et al.. 2005 Phase I trial of a monoclonal antibody specific for αvβ3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion Clin Cancer Res 11 21 7851 7860 10.1158/1078-0432.CCR-05-0262 1:CAS:528: DC%2BD2MXhtF2isL%2FJ 16278408 (Pubitemid 41611630)
36. Stupack DG, Cheresh DA (2002) Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 115(Pt;%19): 3729-3738
37. J Takagi TA Springer 2002 Integrin activation and structural rearrangement Immunol Rev 186 141 163 10.1034/j.1600-065X.2002.18613.x 1:CAS:528:DC%2BD38XotFeht7Y%3D 12234369
38. P Holliger PJ Hudson 2005 Engineered antibody fragments and the rise of single domains Nat Biotechnol 23 9 1126 1136 10.1038/nbt1142 1:CAS:528:DC%2BD2MXpvVyrtrc%3D 16151406 (Pubitemid 41486394)
39. D Colcher G Pavlinkova G Beresford BJ Booth A Choudhury SK Batra 1998 Pharmacokinetics and biodistribution of genetically-engineered antibodies Q J Nucl Med 42 4 225 241 1:STN:280:DyaK1M7jvFansw%3D%3D 9973838 (Pubitemid 29052423)
40. S Mao C Gao CH Lo P Wirsching CH Wong KD Janda 1999 Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx Proc Natl Acad Sci USA 96 12 6953 6958 10.1073/pnas.96.12.6953 1:CAS:528:DyaK1MXks1Wkt7k%3D 10359820 (Pubitemid 29274991)
41. DN Krag SP Fuller L Oligino, et al.. 2002 Phage-displayed random peptide libraries in mice: toxicity after serial panning Cancer Chemother Pharmacol 50 4 325 332 10.1007/s00280-002-0489-4 1:CAS:528:DC%2BD38XnsVamtb4%3D 12357308
42. CC Jaffe 2006 Measures of response: RECIST, WHO, and new alternatives J Clin Oncol 24 20 3245 3251 10.1200/JCO.2006.06.5599 16829648 (Pubitemid 46622065)
43. P Therasse EA Eisenhauer J Verweij 2006 RECIST revisited: a review of validation studies on tumour assessment Eur J Cancer 42 8 1031 1039 10.1016/j.ejca.2006.01.026 1:STN:280:DC%2BD283nt1antQ%3D%3D 16616487
44. EA Eisenhauer P Therasse J Bogaerts, et al.. 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 228 247 10.1016/j.ejca.2008.10.026 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D 19097774
45. Agresti A (1990) Categorical data analysis. Sec. 3.3.7. ed
46. Denault JB, Salvesen GS (2003) Expression, purification, and characterization of caspases. Curr Protoc Protein Sci Chap. 21:Unit 21.13.: Unit
47. HR Stennicke JM Jurgensmeier H Shin, et al.. 1998 Pro-caspase-3 is a major physiologic target of caspase-8 J Biol Chem 273 42 27084 27090 10.1074/jbc.273.42.27084 1:CAS:528:DyaK1cXntVShtr0%3D 9765224 (Pubitemid 28500413)